Meet the Management Team
Our leadership team is responsible for the strategic direction and management of Liminal BioSciences. They are assisted in these responsibilities by our board and advisory members. Each member of the management team is responsible for a specific part of our business.
Bruce was appointed as Chief Executive Officer, effective 13 November 2020. Prior to that he was one of 2 Chief Operating Officers In this role he was responsible for the company’s discovery, clinical development, program management, CMC and business development functions related to Small Molecule Therapeutics.
An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than fourteen years’ experience with Liminal and has held a number of senior global positions across the organisation.
Prior to being appointed CEO he became COO in 2014, previously he was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance.
As well as being a chartered accountant, Bruce also brought to the role many years of experience in general management and operations. Prior to joining Liminal, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company.
Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also a Non-Executive Director and Chair of the Audit Committee of Porton Biopharma Limited, and is Deputy President of The Institute of Chartered Accountants of Scotland.
Bruce is based out of Liminal’s UK office in Cambridge.
Patrick was appointed as President, effective November 13, 2020. Prior to that, he was one of two Chief Operating Officers. In this role, Patrick was responsible for the company’s commercial, marketing, clinical development, manufacturing, and corporate & business development functions, related to Plasma-Derived Therapeutics . A lawyer by training, he has spent over 18 years working in the life sciences and pharmaceutical industry. He has more than fourteen years’ experience with Liminal and has held a number of senior global positions across the organization.
Prior to being appointed COO in 2019, Patrick was the Group Chief Legal Officer and Corporate Secretary, a role he had held since 2015. Patrick brings a proven track record of success in strategic acquisition and licensing transactions and in closing debt and equity financings in various jurisdictions.
As well as being a lawyer, Patrick also brought to the role many years of experience in general intellectual property management, prosecution, commercialization as well as VC financing. Prior to joining Liminal, Patrick worked as a senior counsel for Univalor, a commercialization and VC investment vehicle for life science companies spun out of various Canadian hospitals, institutions and academia. Patrick was also previously employed by Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporate and Commercial Law, as an attorney.
Mr. Sartore graduated from the University of Montreal with a Bachelor of Law (LLB) in 1999 and was called to the Bar of Québec in 2001. Mr. Sartore also holds a Bachelor of Science (BSc), with Distinction, from Concordia University and a specialized graduate diploma (DESS) from HEC Montréal, in Tax.
Murielle Lortie is the Chief Financial Officer of Liminal. She has served as VP Finance of Liminal since September, 2018 and has held multiple senior positions within the pharmaceutical industry over the past 20 years.
Murielle brings a vast amount of experience in finance and corporate strategy. Prior to joining Liminal Murielle was employed as Vice President & Chief Financial Officer and Advisor to the CEO, Global Strategy, Mergers & Acquisitions at Pharmascience Inc. Previous to this, Murielle has held senior positions in finance at Bristol Myers Squibb including Vice-President of Finance for Bristol Myers Squibb Canada Co. and Global Director of Finance supporting BMS Headquarters.
Murielle also served as a Director on the Board of Bellus Health and Pharmascience Barbados Ltd & Pharmascience International Ltd.
Mrs. Lortie is a Chartered Professional Accountant & member of the Ordre des comptables professionnels agrées du Québec. She holds a Graduate Diploma in Accountancy from Concordia University and a Bachelor of Business Administration Bishop’s University.
Marie is General Counsel for the Liminal Group. As General Counsel Marie oversees the legal, compliance, intellectual property and corporate governance functions. Marie is also Corporate Secretary for Liminal.
Moira Daniels is the Head of Regulatory Affairs and Quality Assurance of Liminal. She joined Liminal in November 2019 and has held multiple senior roles within the pharmaceutical industry over the past 35 years.
Moira brings significant experience in product development and regulatory affairs as well as change management within the industry. Prior to Joining Liminal Moira was employed as VP at UCB Pharma, PAREXEL and AstraZeneca holding senior positions in Regulatory Affairs and leading trade association teams on key policy topics at an international level. Moira has worked successfully in different therapeutic areas securing regulatory approvals globally.
Mrs Daniels has a BSc in Biochemistry and Physiology with an MBA from Henley Management College.
Martin Leclerc is the Chief Talent Officer for Liminal BioSciences. As such, he is responsible for developing and executing the human resources strategy to support Liminal’s business plan.
Martin joined Liminal in May 2017 as Vice-President Human Resources. Prior to joining the Company, Martin was Global Leader, Total Rewards for CAE, a global aviation and training company. He has also held a number of senior positions in the human resources field within large global corporations after starting his career as a consulting actuary.
Martin graduated from the Université de Montréal in with a bachelor in Mathematical Sciences and became a Fellow of the Canadian Institute of Actuaries and of the Society of Actuaries.
Dr. Bridger has extensive experience in leading research and development through to commercialisation. Dr. Bridger previously served as Executive Vice President of Research and Development at Xenon Pharmaceuticals Inc., Senior Vice President of Research and Development of Genzyme Corporation and co-founded AnorMED Inc., eventually acquired by Genzyme.
Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc.